Hence, the in vitro targeted therapeutic effect in PBRM1-deficient clear cell renal cell carcinoma (ccRCC) has recently been described, suggesting a possible similar activity in PBRM1-mutated chordoma [29]. This evidence concerns the gene PBRM1 and chordoma.